Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan Effects on Renal Perfusion in Metabolic Syndrome
NCT00452192Phase 3Completed
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- Nov 2006
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of telmisartan in metabolic syndrome, sponsored by FAU Erlangen-Nürnberg Medical Faculty. Started Nov 2006; status: completed.
02
Drugs
telmisartan
03
Conditions
metabolic syndrome
Beyond the preview
Go deeper on NCT00452192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00452192.